Resolute ZES (zotarolimus-eluting stent) / Medtronic 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«1234567891011»
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    Trial completion, Trial completion date:  RESOLUTE ONYX Post-Approval Study (Bifurcation Cohort) (clinicaltrials.gov) -  May 1, 2023   
    P=N/A,  N=205, Completed, 
    In our single-center, all-comer registry, 2G-DES had better efficacy especially repeat revascularization compared with 1G-DES in UA patients during 10-year follow-up periods. Active, not recruiting --> Completed | Trial completion date: Aug 2023 --> Sep 2022
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    Trial completion date, Trial primary completion date, Combination therapy:  Bioflow-DAPT Study (clinicaltrials.gov) -  Apr 12, 2023   
    P4,  N=1948, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Aug 2023 --> Sep 2022 Trial completion date: Apr 2023 --> Feb 2027 | Trial primary completion date: Apr 2023 --> Jan 2023
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    Trial completion date:  China Resolute Integrity 34/38 mm Study (clinicaltrials.gov) -  Apr 12, 2023   
    P=N/A,  N=40, Active, not recruiting, 
    Trial completion date: Apr 2023 --> Feb 2027 | Trial primary completion date: Apr 2023 --> Jan 2023 Trial completion date: Dec 2023 --> Apr 2023
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    Trial completion date:  RESOLUTE ONYX Post-Approval Study (Bifurcation Cohort) (clinicaltrials.gov) -  Mar 27, 2023   
    P=N/A,  N=205, Active, not recruiting, 
    Trial primary completion date: Sep 2022 --> Apr 2023 Trial completion date: Jan 2023 --> Aug 2023
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    Journal:  Long-term follow-up of contemporary (Pubmed Central) -  Mar 2, 2023   
    This subanalysis shows that the use of PF-AES results in similar clinical outcomes as compared to PP-ZES, yet some benefits of use of PF-AES in diabetic patients may prevail. Future dedicated trials should confirm these findings.
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    Trial completion date, Trial suspension:  The Rolex Registry (Revascularization Of LEft Main With Resolute onyX) (clinicaltrials.gov) -  Jan 31, 2023   
    P=N/A,  N=450, Suspended, 
    Trial completion date: Dec 2022 --> Jun 2023 Trial completion date: Dec 2022 --> Dec 2025 | Active, not recruiting --> Suspended
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    UNDEPLOYED STENT HARDWARE DISCOVERED AFTER 10 YEARS IN CORONARY ARTERY WITHOUT CORONARY THROMBOSIS (Room 207; [In-Person]; [ACC Anywhere]) -  Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_2904;    
    A Resolute Onyx 5mm x 30mm stent was positioned in the mid RCA and was deployed at 14 atmospheres for 10 seconds, resulting in balloon rupture...Post deployment dilation was completed with a non-compliant Euphora balloon, with four inflations at 22 atmospheres for 10 seconds. The IVUS catheter was then passed through the entire RCA and showed that the prior stent had been crushed to the vessel wall, and the two new stents were well apposed to the vessel wall.
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    PERIPARTUM SPONTANEOUS CORONARY ARTERY DISSECTION COMPLICATED BY VENTRICULAR FIBRILLATION ARREST AND CIRCULATORY SHOCK (Poster Hall_Hall F) -  Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_2530;    
    ECG on arrival was notable for anterior ST elevation prompting emergent coronary angiography, which revealed Type 2 SCAD involving the mid left anterior descending artery (LAD) with TIMI 0 flow and Type 1 SCAD involving the ostial to distal right coronary artery (RCA) with TIMI 3 flow (Figure 1).Decision?making: Given hemodynamic and electrical instability in the setting of total LAD occlusion, patient underwent PCI of the LAD with placement of two drug eluting stents in tapering fashion (Resolute Onyx 2.25 x 38mm, 2.5 x 18mm), achieving TIMI 3 flow... Conservative management is preferred for SCAD, however this was a high-risk case requiring coronary intervention.
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    Trial completion date, Trial primary completion date:  IRIS-Onyx Cohort in the IRIS-DES Registry (clinicaltrials.gov) -  Dec 13, 2022   
    P=N/A,  N=4000, Recruiting, 
    Conservative management is preferred for SCAD, however this was a high-risk case requiring coronary intervention. Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2022 --> Sep 2023
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
    Journal:  Comparison of Contemporary Drug-Eluting Stents in Patients Undergoing Complex High-Risk Indicated Procedures. (Pubmed Central) -  Nov 8, 2022   
    P=N/A
    However, owing to inherent selection bias, the results should be considered hypothesis-generating, highlighting the need for further randomized trials. (Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice [IRIS-DES]; NCT01186133).
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
    Clinical, Journal:  Comparison of Different Types of Drug-Eluting Stents for De Novo Long Coronary Artery Lesions. (Pubmed Central) -  Nov 8, 2022   
    P4
    In this patient-level pooled analysis, several second-generation DES showed similar angiographic and clinical outcomes in patients with de novo long coronary lesions. (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III [LONG-DES-III]; NCT01078038; Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-IV [LONG-DES-IV]; NCT01186094; and Everolimus-eluting [PROMUS-ELEMENT] vs. Biolimus A9-Eluting [NOBORI] Stents for Long-Coronary Lesions [LONG-DES-V]; NCT01186120).
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    Trial completion:  ONYX PAS: RESOLUTE ONYX Post-Approval Study (clinicaltrials.gov) -  Oct 27, 2022   
    P=N/A,  N=416, Completed, 
    However, this analysis is only based on a follow-up time period of one year, therefore, future research should focus on the long term follow-up time period. Active, not recruiting --> Completed
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    New trial, Combination therapy:  BIOFLOW-DAPT: BIOFLOW-Dual Anti-Platelet Therapy (clinicaltrials.gov) -  Sep 22, 2022   
    P=N/A,  N=50, Recruiting, 
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    Retrospective data, Journal:  Subclavian-carotid transposition and subclavian artery stenting for steal-syndrome (Pubmed Central) -  Sep 16, 2022   
    In turn, subclavian artery stenting is associated with the risk of dissection and embolism. Therefore, the choice of treatment strategy in patients with occlusive-stenotic lesions of the first segment of subclavian artery should be personalized and carried out by a multidisciplinary team.
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    Enrollment closed:  The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries (clinicaltrials.gov) -  Aug 1, 2022   
    P=N/A,  N=444, Active, not recruiting, 
    We report a rare case of cardiac arrest due to 100% thrombotic occlusion of culprit anomalous LAD originating from RCA leading to acute anterior wall myocardial infarction. Recruiting --> Active, not recruiting
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
    Trial primary completion date:  TARGET-IV_NA: Firehawk Rapamycin Target Eluting Coronary Stent North American Trial (clinicaltrials.gov) -  Jul 23, 2022   
    P=N/A,  N=1720, Recruiting, 
    Recruiting --> Active, not recruiting Trial primary completion date: Jun 2023 --> Jun 2024
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    Trial completion date, Trial primary completion date:  Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT) (clinicaltrials.gov) -  Jul 20, 2022   
    P=N/A,  N=2400, Recruiting, 
    Trial primary completion date: Jun 2023 --> Jun 2024 Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
    Journal:  Stent dislodgement force of drug-eluting coronary stents: a bench test. (Pubmed Central) -  Jul 10, 2022   
    The Orsiro stent was lower than that of other DES; additionally, it easily removed the whole stent from the delivery system. During the coronary intervention, operators should consider stent design and be cautious when pulling DES back in lesions with calcifications or a previously implanted stent, which are at high risk for stent dislodgement.